A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin
(2020)
Journal Article
Jones, R., Crabb, S., Chester, J., Elliott, T., Huddart, R., Birtle, A., Evans, L., Lester, J., Jagdev, S., Casbard, A., Huang, C., Madden, T. A., & Griffiths, G. (2020). A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin. BJU international, 126(2), 292-299. https://doi.org/10.1111/bju.15096
Objectives To assess the efficacy and tolerability of the dual epidermal growth factor receptor/vascular endothelial growth factor receptor inhibitor, vandetanib, in combination with carboplatin and gemcitabine in the first‐line treatment of patient... Read More about A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.